Studien der Onkologischen Tagesklinik

MONTBLANC

firstline
Sequential vs. up-front triple treatment with of durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients

SOLARIS

secondline
A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy

ABC-HCC

firstline
A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma with high disease burden

KEYNOTE 937

adjuvant
Pembrolizumab (MK-3475) versus Placebo als adjuvante Therapie bei Patienten mit HCC und radiologischer Komplettremission nach chirurgischer Resektion oder lokaler Ablation

AIO-HEP 0418 DEMAND
firstline
A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients

IMMUWIN

firstline
A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design

AURORA
secondline
A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to LenvAtinib Treatment

CaboRise

secondline
A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis

ADVANCE

firstline
A phase II single-arm, open-label study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements

RAMIRIS

secondline

Ramucirumab plus Irinotecan / Leucovorin / 5-Fu versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy

INNOVATION
neoadjuvant - adjuvant
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer

MOONLIGHT
firstline
Modifiziertes FOLFOX mit Nivolumab und Ipilimumab bei Patienten mit unbehandeltem, lokal fortgeschrittenen oder metastasierten Adenokarzinom des Magens oder des gastroösophagealen Übergangs. Eine randomisierte Phase 2 Studie

HOLIPANC

adjuvant
Non-randomised, open phase II trial investigating efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5 fluorouracil/folinic acid and oxaliplatin followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas

PROJECTION

adjuvant
Prognostic role of circulating tumor DNA in resectable Pancreatic Cancer

AIO-PAK-0114 ALPACA
firstline
Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study

FOOTPATH
firstline
A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer